Premium
Blood and bone marrow eosinophilia in malignant tumors. Role and nature of blood and tissue eosinophil colony‐stimulating factor(s) in two patients
Author(s) -
Stefanini Mario,
Motos Ramon A.,
Bendigo Leopoldo L.,
Claustro Joseph C.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910801)68:3<543::aid-cncr2820680317>3.0.co;2-3
Subject(s) - eosinophilia , eosinophil , medicine , bone marrow , macrophage colony stimulating factor , pathogenesis , colony stimulating factor , pathology , granulocyte macrophage colony stimulating factor , granulocyte colony stimulating factor , immunology , cytokine , haematopoiesis , macrophage , biology , chemotherapy , stem cell , biochemistry , genetics , asthma , in vitro
Eosinophilia of the blood and bone marrow may be encountered in patients with disseminated malignancies. It is unrelated to the histologic type of the tumor but usually reflects its aggressiveness and prognostic outlook. Its pathogenesis is controversial. The presence of eosinophil colony‐stimulating factor(s) in serum and malignant tissue extracts was evaluated in two cases of malignancies accompanied by marked blood and bone marrow eosinophilia. When compared with controls, serum and tumor tissue extracts stimulated the growth of G, M, and Eo colonies in semisolid cultures of human bone marrow. Such stimulating effect was inhibited by the addition of antibodies to granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) and interleukin‐3. Thus, the colony‐stimulating factor(s) play a role in the pathogenesis of the eosinophilia associated with some malignant tumors, and these factors appear to include GM‐CSF, interleukin‐3, and probably others.